{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:06:40Z","timestamp":1789330000559,"version":"build-2803163510"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004605","name":"Zhengzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004605","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clon.2026.104171","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:06:34Z","timestamp":1776899194000},"page":"104171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Management of Medullary Thyroid Carcinoma: Integrating World Health Organization Grading and Molecular Targets for Precision Therapy"],"prefix":"10.1016","volume":"55","author":[{"given":"M.H.","family":"Arawker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Habibullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.-H.","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Baral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2772-7456","authenticated-orcid":false,"given":"X.","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2026.104171_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/cncy.70023","article-title":"The diagnostic challenges of medullary thyroid carcinoma: a practical guide for cytopathologists","volume":"133","author":"Pusztaszeri","year":"2025","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.clon.2026.104171_bib2","doi-asserted-by":"crossref","unstructured":"Hauache OM, Vieira JGH, Maciel RMB. Diagn\u00f3stico laboratorial do carcinoma medular de tir\u00f3ide: calcitonina basal e testes de est\u00edmulo. Arq Bras Endocrinol Metab.47:529-533. https:\/\/doi.org\/10.1590\/s0004-27302003000500005.","DOI":"10.1590\/S0004-27302003000500005"},{"key":"10.1016\/j.clon.2026.104171_bib3","first-page":"57","article-title":"Advanced medullary thyroid cancer: pathophysiology and management","volume":"5","author":"Ferreira","year":"2013","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clon.2026.104171_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.semnuclmed.2016.01.010","article-title":"Peptide receptor radionuclide therapy (PRRT) of medullary and nonmedullary thyroid cancer using radiolabeled somatostatin analogues","volume":"46","author":"Salavati","year":"2016","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.clon.2026.104171_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153643","article-title":"Update on the diagnosis and management of medullary thyroid cancer: what has changed in recent years?","volume":"14","author":"Kaliszewski","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104171_bib6","doi-asserted-by":"crossref","unstructured":"Kim M, Kim BH. Current guidelines for management of medullary thyroid carcinoma. Endocrinol Metab.36:514-524. https:\/\/doi.org\/10.3803\/enm.2021.1082.","DOI":"10.3803\/EnM.2021.1082"},{"key":"10.1016\/j.clon.2026.104171_bib7","first-page":"6098","article-title":"A new proposed tumor-node-metastasis-age staging system for stage IV medullary thyroid carcinoma based on the SEER database","volume":"13","author":"Li","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.clon.2026.104171_bib8","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2174\/138920211798120835","article-title":"Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers","volume":"12","author":"A","year":"2011","journal-title":"Curr Genomics"},{"key":"10.1016\/j.clon.2026.104171_bib9","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1186\/s12885-025-15101-z","article-title":"Anatomical\u2013biochemical discordance and prognostic role of bone metastases in advanced MTC treated with [177Lu]Lu-DOTA-TATE","volume":"25","author":"Bilgic","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2026.104171_bib10","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1007\/s00268-018-4738-z","article-title":"Static prognostic factors and appropriate surgical designs for patients with medullary thyroid carcinoma: the second report from a single-institution study in Japan","volume":"42","author":"Ito","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.clon.2026.104171_bib11","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3803\/EnM.2016.31.3.392","article-title":"Recent updates on the management of medullary thyroid carcinoma","volume":"31","author":"Kim","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.clon.2026.104171_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1094242","article-title":"Early postoperative calcitonin-to-preoperative calcitonin ratio as a predictive marker for structural recurrence in sporadic medullary thyroid cancer: A retrospective study","volume":"13","author":"Jiao","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clon.2026.104171_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/CMAR.S440477","article-title":"Serum biochemical markers for medullary thyroid carcinoma: an update","volume":"16","author":"Liu","year":"2024","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.clon.2026.104171_bib14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.clon.2026.104171_bib15","doi-asserted-by":"crossref","unstructured":"Asa SL, Mete O. Medullary thyroid carcinoma in the IARC\/WHO neuroendocrine schema. Endocr Pathol.33:346-347. https:\/\/doi.org\/10.1007\/s12022-022-09728-y.","DOI":"10.1007\/s12022-022-09728-y"},{"key":"10.1016\/j.clon.2026.104171_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvac009","article-title":"Other markers of medullary thyroid cancer, not only calcitonin","volume":"188","author":"Censi","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.clon.2026.104171_bib17","first-page":"221","article-title":"Molecular basis of medullary thyroid carcinoma: The role of RET polymorphisms","author":"Ceolin","year":"2012","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clon.2026.104171_bib18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.21.01329","article-title":"International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/genes10090698","article-title":"Twenty-five years experience on RET genetic screening on hereditary MTC: An update on the prevalence of germline RET mutations","volume":"10","author":"Elisei","year":"2019","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.clon.2026.104171_bib20","doi-asserted-by":"crossref","unstructured":"Jung CK, Bychkov A, Kakudo K. Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach. Endocrinol Metab.37:703-718. https:\/\/doi.org\/10.3803\/enm.2022.1553.","DOI":"10.3803\/EnM.2022.1553"},{"key":"10.1016\/j.clon.2026.104171_bib21","series-title":"Endocrine and neuroendocrine tumours","year":"2022"},{"key":"10.1016\/j.clon.2026.104171_bib22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3803\/EnM.2022.1553","article-title":"Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach","volume":"37","author":"Jung","year":"2022","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.clon.2026.104171_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41379-020-0532-1","article-title":"Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome","volume":"33","author":"Alzumaili","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clon.2026.104171_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16050917","article-title":"Latest progress in risk-adapted surgery for medullary thyroid cancer","author":"Machens","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.clon.2026.104171_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.866572","article-title":"Is encapsulated medullary thyroid carcinoma associated with a better prognosis? a case series and a review of the literature","volume":"13","author":"Contarino","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clon.2026.104171_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s12022-013-9287-2","article-title":"Medullary thyroid carcinoma: a 25-year perspective","volume":"25","author":"Matias-Guiu","year":"2014","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.clon.2026.104171_bib27","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1097\/JS9.0000000000002816","article-title":"Dynamic risk stratification-guided management of medullary thyroid carcinoma: integrating surgical precision with RET-targeted therapies and molecular surveillance","volume":"111","author":"Zhang","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.clon.2026.104171_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2023.0482","article-title":"Tumor grade and molecular characteristics associated with survival in sporadic medullary thyroid carcinoma","volume":"34","author":"Censi","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.clon.2026.104171_bib29","doi-asserted-by":"crossref","unstructured":"Viswanathan K, Behrman DB, Lubin DJ. Grading medullary thyroid carcinoma on fine-needle aspiration cytology specimens with the International Medullary Thyroid Carcinoma Grading System: A cytologic\u2013histologic correlation. Cancer Cytopathology.132:224-232. https:\/\/doi.org\/10.1002\/cncy.22778.","DOI":"10.1002\/cncy.22778"},{"key":"10.1016\/j.clon.2026.104171_bib30","doi-asserted-by":"crossref","unstructured":"Williams JF, Zhao M, Najdawi F, Ahmadi S, Hornick JL, Wong KS, et al. Grading of medullary thyroid carcinoma: an Interobserver Reproducibility Study. Endocr Pathol.33:371-377. https:\/\/doi.org\/10.1007\/s12022-022-09718-0.","DOI":"10.1007\/s12022-022-09718-0"},{"key":"10.1016\/j.clon.2026.104171_bib31","doi-asserted-by":"crossref","DOI":"10.1007\/s12022-022-09718-0","article-title":"Grading of medullary thyroid carcinoma: an Interobserver Reproducibility Study","volume":"33","author":"Williams","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.clon.2026.104171_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151586","article-title":"Ki67 index and mitotic count: correlation and variables affecting the accuracy of the quantification in endocrine\/neuroendocrine tumors","volume":"48","author":"Huang","year":"2020","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.clon.2026.104171_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100235","article-title":"Independent validation of the international grading system for medullary thyroid carcinoma: a single institution experience","volume":"36","author":"Lubin","year":"2023","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clon.2026.104171_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132296","article-title":"Medullary thyroid cancer: molecular drivers and immune cellular milieu of the tumour microenvironment\u2014implications for systemic treatment","author":"Papachristos","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.clon.2026.104171_bib35","doi-asserted-by":"crossref","first-page":"R251","DOI":"10.1530\/EC-20-0374","article-title":"Current status of the prognostic molecular markers in medullary thyroid carcinoma","volume":"9","author":"Oczko-Wojciechowska","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1016\/j.clon.2026.104171_bib36","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12935-025-03734-w","article-title":"Intratumoral heterogeneity and drug resistance in cancer","volume":"25","author":"Fu","year":"2025","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.clon.2026.104171_bib37","first-page":"23","article-title":"Systemic treatment of advanced, metastatic, medullary thyroid carcinoma","volume":"7","author":"Antonio","year":"2021","journal-title":"J Cancer Metastasis Treat"},{"key":"10.1016\/j.clon.2026.104171_bib38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/thy.2005.15.531","article-title":"RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors","volume":"15","author":"Kouvaraki","year":"2005","journal-title":"Thyroid"},{"key":"10.1016\/j.clon.2026.104171_bib39","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12964-024-01837-x","article-title":"Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell Commun Signaling"},{"key":"10.1016\/j.clon.2026.104171_bib40","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.21037\/gs-2019-catp-21","article-title":"Updates in the advances of sporadic medullary thyroid carcinoma: from the molecules to the clinic","volume":"9","author":"Bai","year":"2020","journal-title":"Gland Surg"},{"key":"10.1016\/j.clon.2026.104171_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194865","article-title":"Molecular basis and natural history of medullary thyroid cancer: it is (Almost) all in the RET","author":"Sahakian","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.clon.2026.104171_bib42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.clon.2026.104171_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14081951","article-title":"Medullary thyroid carcinoma mutational spectrum update and signaling-type inference by transcriptional profiles: literature meta-analysis and study of tumor samples","volume":"14","author":"Minna","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104171_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132296","article-title":"Medullary thyroid cancer: molecular drivers and immune cellular milieu of the tumour microenvironment-implications for systemic treatment","volume":"16","author":"Papachristos","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104171_bib45","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41421-022-00479-y","article-title":"Integrated proteogenomic characterization of medullary thyroid carcinoma","volume":"8","author":"Shi","year":"2022","journal-title":"Cell Discov"},{"key":"10.1016\/j.clon.2026.104171_bib46","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1158\/1078-0432.CCR-16-0947","article-title":"Multilayer OMIC data in medullary thyroid carcinoma identifies the STAT3 pathway as a potential therapeutic target in RET tumors","volume":"23","author":"Mancikova","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clon.2026.104171_bib47","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-021-01091-5","article-title":"TET2 and DNMT3A mutations and exceptional response to 4\u2032-thio-2\u2032-deoxycytidine in human solid tumor models","volume":"14","author":"Yang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib48","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature09727","article-title":"CREBBP mutations in relapsed acute lymphoblastic leukaemia","volume":"471","author":"Mullighan","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clon.2026.104171_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOH.0000000000000688","article-title":"Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease","volume":"29","author":"Cobo","year":"2022","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clon.2026.104171_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.901435","article-title":"Epigenetic regulation in gastroenteropancreatic neuroendocrine tumors","volume":"12","author":"Crabtree","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1530\/EC-20-0611","article-title":"DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas","volume":"10","author":"Ingenwerth","year":"2021","journal-title":"Endocr Connect"},{"key":"10.1016\/j.clon.2026.104171_bib52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12022-024-09817-0","article-title":"Transcriptomic differences in medullary thyroid carcinoma according to grade","volume":"35","author":"Ruz-Caracuel","year":"2024","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.clon.2026.104171_bib53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib54","doi-asserted-by":"crossref","DOI":"10.1530\/EC-20-0611","article-title":"DLL3 (delta like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas","volume":"10","author":"Ingenwerth","year":"2021","journal-title":"Endocr Connections"},{"key":"10.1016\/j.clon.2026.104171_bib55","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","article-title":"DLL3 as an emerging target for the treatment of neuroendocrine neoplasms","volume":"27","author":"Yao","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.clon.2026.104171_bib56","article-title":"Targeting DLL3 in small cell lung cancer and other neuroendocrine carcinomas","volume":"7","author":"Aubrey","year":"2025","journal-title":"Pharm Pract Focus: Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib57","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib58","series-title":"Open-label study of IBI3009 in participants with unresectable, metastatic or extensive-stage small cell lung cancer","year":"2024"},{"key":"10.1016\/j.clon.2026.104171_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14165645","article-title":"Circulating biomarkers in medullary thyroid carcinoma: bridging laboratory complexities and clinical application through algorithm design","author":"Giovanella","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.clon.2026.104171_bib60","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.surg.2011.09.043","article-title":"Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma","volume":"150","author":"Yip","year":"2011","journal-title":"Surgery"},{"key":"10.1016\/j.clon.2026.104171_bib61","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12902-019-0367-2","article-title":"Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?","volume":"19","author":"Gambardella","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.clon.2026.104171_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/biom15071011","article-title":"The future of tumor markers: advancing early malignancy detection through omics technologies, continuous monitoring, and personalized reference intervals","volume":"15","author":"Savas","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.clon.2026.104171_bib63","first-page":"19","article-title":"Role of Tc-99m DMSA (V) scanning and serum calcitonin monitoring in the management of medullary thyroid carcinoma","volume":"49","author":"Howe","year":"2008","journal-title":"Singapore Med J"},{"key":"10.1016\/j.clon.2026.104171_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14165645","article-title":"Circulating biomarkers in medullary thyroid carcinoma: bridging laboratory complexities and clinical application through algorithm design","volume":"14","author":"Giovanella","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.clon.2026.104171_bib65","article-title":"Multiple immunoassay interference in a patient with falsely elevated calcitonin","volume":"68","author":"Unal","year":"2023","journal-title":"Arch Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.clon.2026.104171_bib66","doi-asserted-by":"crossref","DOI":"10.21037\/gs-24-292","article-title":"Diagnostic challenges in calcitonin negative medullary thyroid carcinoma: a systematic review of 101 cases","volume":"13","author":"Abaalkhail","year":"2024","journal-title":"Gland Surg"},{"key":"10.1016\/j.clon.2026.104171_bib67","doi-asserted-by":"crossref","first-page":"32","DOI":"10.53853\/encr.3.4.14","article-title":"Sporadic calcitonin-negative medullary thyroid carcinoma is not more aggressive than its classic counterpart: case report and review of the literature","volume":"3","author":"Orrego","year":"2016","journal-title":"Rev Colomb Endocrinol Diab Metabol"},{"key":"10.1016\/j.clon.2026.104171_bib68","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12902-019-0367-2","article-title":"Calcitonin negative Medullary Thyroid Carcinoma: a challenging diagnosis or a medical dilemma?","volume":"19","author":"Gambardella","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.clon.2026.104171_bib69","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.21037\/gs-24-292","article-title":"Diagnostic challenges in calcitonin negative medullary thyroid carcinoma: a systematic review of 101 cases","volume":"13","author":"Abaalkhail","year":"2024","journal-title":"Gland Surg"},{"key":"10.1016\/j.clon.2026.104171_bib70","doi-asserted-by":"crossref","unstructured":"Gonzales Laguado E, Garc\u00eda Ruiz L, Guerra Miller H, Luna-Abanto J. Carcinoma neuroendocrino de tiroides calcitonina negativa: reporte de caso y revisi\u00f3n de la literatura. Rev Med Hered.32:119-123. https:\/\/doi.org\/10.20453\/rmh.v32i2.3986.","DOI":"10.20453\/rmh.v32i2.3986"},{"key":"10.1016\/j.clon.2026.104171_bib71","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1210\/jc.2008-1862","article-title":"Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma","volume":"94","author":"Algeciras-Schimnich","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2026.104171_bib72","article-title":"Medullary thyroid carcinoma with elevated serum cea and normal serum calcitonin after surgery: a case report and literature review","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib73","article-title":"Liquid biopsy: an evolving paradigm for non-invasive disease diagnosis and monitoring in medicine","volume":"15","author":"Adhit","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.clon.2026.104171_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100060","article-title":"How to use liquid biopsies to treat patients with cancer","volume":"6","author":"De Mattos-Arruda","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.clon.2026.104171_bib75","doi-asserted-by":"crossref","first-page":"e3420","DOI":"10.1210\/clinem\/dgac222","article-title":"Pre- and post-operative circulating tumoral DNA in patients with medullary thyroid carcinoma","volume":"107","author":"Ciampi","year":"2022","journal-title":"The J Clin Endocrinol Metab"},{"key":"10.1016\/j.clon.2026.104171_bib76","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1477-7819-4-97","article-title":"Serum calcitonin negative medullary thyroid carcinoma","volume":"4","author":"Sand","year":"2006","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.647369","article-title":"Serum miR-375 for diagnostic and prognostic purposes in medullary thyroid carcinoma","volume":"12","author":"Censi","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clon.2026.104171_bib78","article-title":"From circulating tumor cells to mirna: new challenges in the diagnosis and prognosis of medullary thyroid","volume":"15","author":"Ricci","year":"2023","journal-title":"Cancer Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104171_bib79","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00428-017-2227-7","article-title":"MiR-375 and YAP1 expression profiling in medullary thyroid carcinoma and their correlation with clinical-pathological features and outcome","volume":"471","author":"Galuppini","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.clon.2026.104171_bib80","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211049611","article-title":"Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis","volume":"12","author":"Bartz-Kurycki","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.clon.2026.104171_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cells10040955","article-title":"MicroRNAs in medullary thyroid carcinoma: a state of the art review of the regulatory mechanisms and future perspectives","volume":"10","author":"Galuppini","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.clon.2026.104171_bib82","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.585","article-title":"Challenges of microRNA-based biomarkers in clinical application for cardiovascular diseases","volume":"12","author":"de Gonzalo-Calvo","year":"2022","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.clon.2026.104171_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020276","article-title":"miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis","volume":"9","author":"Condrat","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.clon.2026.104171_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100301","article-title":"International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors","volume":"8","author":"Fusco","year":"2025","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.clon.2026.104171_bib85","doi-asserted-by":"crossref","unstructured":"Zendjabil M. Preanalytical, analytical and postanalytical considerations in circulating microRNAs measurement. Biochem Med.34:186-196. https:\/\/doi.org\/10.11613\/bm.2024.020501.","DOI":"10.11613\/BM.2024.020501"},{"key":"10.1016\/j.clon.2026.104171_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100319","article-title":"Implementation of circulating tumor DNA (ctDNA) testing in precision oncology: A four-year experience from a tertiary cancer center in India","volume":"9","author":"Joshi","year":"2025","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.clon.2026.104171_bib87","article-title":"Considerations and suggestions for the reliable analysis of miRNA in plasma using qRT-PCR","author":"Ban","year":"2022","journal-title":"In: Genes"},{"key":"10.1016\/j.clon.2026.104171_bib88","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.clon.2026.104171_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16203469","article-title":"Holomics and artificial intelligence-driven precision oncology for medullary thyroid carcinoma: addressing challenges of a rare and aggressive disease","volume":"16","author":"Luvhengo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104171_bib90","article-title":"Medullary thyroid carcinoma with elevated serum CEA and normal serum calcitonin after surgery: a case report and literature review","volume":"10","author":"Chen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1579205","article-title":"Spatial immune profiling reveals distinct microenvironments in medullary thyroid carcinoma","volume":"16","author":"de Castro","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clon.2026.104171_bib92","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1089\/thy.1996.6.613","article-title":"Prognostic impact of thyroid lymphocytic infiltration in patients with medullary thyroid carcinoma","volume":"6","author":"Scopsi","year":"1996","journal-title":"Thyroid"},{"key":"10.1016\/j.clon.2026.104171_bib93","article-title":"Immune landscape of thyroid cancers: new insights","volume":"11","author":"Menicali","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clon.2026.104171_bib94","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/thy.2024.0595","article-title":"Tumor-infiltrating lymphocytes assessed using the International TILs working group system are not prognostic in medullary thyroid cancer","volume":"35","author":"Papachristos","year":"2025","journal-title":"Thyroid"},{"key":"10.1016\/j.clon.2026.104171_bib95","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","article-title":"Regulatory T cells in immune checkpoint blockade antitumor therapy","volume":"23","author":"Zhang","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clon.2026.104171_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1677548","article-title":"Reprogramming the tumor microenvironment to boost adoptive T cell therapy","volume":"16","author":"Meza Pacheco","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clon.2026.104171_bib97","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12967-023-04810-3","article-title":"Matrix stiffness affects tumor-associated macrophage functional polarization and its potential in tumor therapy","volume":"22","author":"Xiong","year":"2024","journal-title":"J Translational Med"},{"key":"10.1016\/j.clon.2026.104171_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100183","article-title":"How I treat medullary thyroid cancer","volume":"6","author":"Kiesewetter","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.clon.2026.104171_bib99","doi-asserted-by":"crossref","first-page":"L35","DOI":"10.1530\/ERC-17-0104","article-title":"Very low expression of PD-L1 in medullary thyroid carcinoma","volume":"24","author":"Bongiovanni","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clon.2026.104171_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.343","article-title":"Hot and cold tumors: Immunological features and the therapeutic strategies","volume":"4","author":"Wang","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.clon.2026.104171_bib101","article-title":"CAR-T cell therapy in advanced thyroid cancer: from basic to clinical","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.clon.2026.104171_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2025.105493","article-title":"A perspective on integrating digital pathology, proteomics, clinical data and AI analytics in cancer research","volume":"320","author":"Guedes","year":"2025","journal-title":"J Proteomics"},{"key":"10.1016\/j.clon.2026.104171_bib103","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12935-025-03944-2","article-title":"Integration of multi-omics approaches in exploring intra-tumoral heterogeneity","volume":"25","author":"Dong","year":"2025","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.clon.2026.104171_bib104","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-022-00446-5","article-title":"Cancer proteogenomics: current impact and future prospects","volume":"22","author":"Mani","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clon.2026.104171_bib105","article-title":"Parallel proteomics and phosphoproteomics defines starvation signal specific processes in cell quiescence","author":"Sun","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.clon.2026.104171_bib106","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/705036","article-title":"Genetic and clinical features of multiple endocrine neoplasia types 1 and 2","volume":"2012","author":"Romei","year":"2012","journal-title":"J Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib107","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1210\/js.2018-00178","article-title":"Update on multiple endocrine neoplasia type 2: focus on medullary thyroid carcinoma","volume":"2","author":"Raue","year":"2018","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.clon.2026.104171_bib108","doi-asserted-by":"crossref","DOI":"10.1177\/03000605221110698","article-title":"Management of medullary carcinoma of the thyroid: a review","volume":"50","author":"Jayasinghe","year":"2022","journal-title":"J Int Med Res"},{"key":"10.1016\/j.clon.2026.104171_bib109","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3803\/EnM.2021.1082","article-title":"Current guidelines for management of medullary thyroid carcinoma","volume":"36","author":"Kim","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.clon.2026.104171_bib110","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3803\/EnM.2022.1553","article-title":"Update from the 2022 World Health Organization classification of thyroid tumors: a standardized diagnostic approach","volume":"37","author":"Jung","year":"2022","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1016\/j.clon.2026.104171_bib111","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S2213-8587(21)00152-2","article-title":"Targeting RET-mutated thyroid and lung cancer in the personalised medicine era","volume":"9","author":"Klubo-Gwiezdzinska","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clon.2026.104171_bib112","first-page":"142","article-title":"Genetic and epigenetic of medullary thyroid cancer","volume":"22","author":"Khatami","year":"2018","journal-title":"Iran Biomed J"},{"key":"10.1016\/j.clon.2026.104171_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1141314","article-title":"Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe","volume":"13","author":"Elisei","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib114","doi-asserted-by":"crossref","first-page":"9875","DOI":"10.18632\/oncotarget.23986","article-title":"RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases","volume":"9","author":"Romei","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clon.2026.104171_bib115","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib116","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clon.2026.104171_bib117","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/XCS.0000000000001098","article-title":"Genomic and transcriptomic landscape of RET wild-type medullary thyroid cancer and potential use of mitogen-activated protein kinase-targeted therapy","volume":"239","author":"Darabi","year":"2024","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.clon.2026.104171_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17040520","article-title":"Targeting DLL3: innovative strategies for tumor treatment","volume":"17","author":"Wang","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clon.2026.104171_bib119","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib120","article-title":"Validation of the International medullary thyroid cancer grading system and identification of EZH2 as a prognostic and potential therapeutic marker in medullary thyroid cancer","author":"Jager","year":"2025","journal-title":"In: Cancers"},{"key":"10.1016\/j.clon.2026.104171_bib121","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1080\/15384047.2018.1523856","article-title":"Mutations of genes including DNMT3A detected by next-generation sequencing in thyroid cancer","volume":"20","author":"Guo","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clon.2026.104171_bib122","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1158\/1538-7445.AM2023-3068","article-title":"Abstract 3068: CREBBP\/EP300 disruption promotes tumor progression and confers synthetic lethality in anaplastic thyroid cancers","volume":"83","author":"Haase","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.clon.2026.104171_bib123","doi-asserted-by":"crossref","first-page":"158","DOI":"10.6004\/jadpro.2022.13.2.7","article-title":"Tazemetostat: EZH2 Inhibitor","volume":"13","author":"Straining","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.clon.2026.104171_bib124","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3390\/ph3072022","article-title":"Demethylating agents in the treatment of cancer","volume":"3","author":"Howell","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clon.2026.104171_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12121214","article-title":"Reprogramming of cellular metabolism and its therapeutic applications in thyroid cancer","volume":"12","author":"Nagayama","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.clon.2026.104171_bib126","first-page":"106","article-title":"PD-L1 expression in medullary thyroid carcinoma and its association with clinicopathological findings","volume":"38","author":"Kemal","year":"2022","journal-title":"Turk Patoloji Derg"},{"key":"10.1016\/j.clon.2026.104171_bib127","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1695716","article-title":"CAR-T therapy for neuroendocrine neoplasms: a review of molecular targets and clinical translation","volume":"16","author":"Golounina","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.clon.2026.104171_bib128","article-title":"Enhancing the efficacy of CAR T cells in the tumor microenvironment of pancreatic cancer","author":"Henze","year":"2020","journal-title":"In: Cancers"},{"key":"10.1016\/j.clon.2026.104171_bib129","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12885-022-10421-w","article-title":"Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkers","volume":"23","author":"Haslam","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2026.104171_bib130","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/ijc.30620","article-title":"The feasibility of using mutation detection in ctDNA to assess tumor dynamics","volume":"140","author":"Yi","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clon.2026.104171_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107458","article-title":"Circulating tumor DNA as an early cancer detection tool","volume":"207","author":"Campos-Carrillo","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clon.2026.104171_bib132","doi-asserted-by":"crossref","unstructured":"Prete A, Gambale C, Torregrossa L, Bottici V, Cappagli V, Basolo F, et al. A new grading system for medullary thyroid cancer. EJEA. https:\/\/doi.org\/10.1530\/endoabs.81.oc11.6.","DOI":"10.1530\/endoabs.81.OC11.6"},{"key":"10.1016\/j.clon.2026.104171_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082333","article-title":"Update on calcitonin screening for medullary thyroid carcinoma and the results of a retrospective analysis of 12,984 patients with thyroid nodules","volume":"15","author":"Broecker-Preuss","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104171_bib134","article-title":"Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules","volume":"3","author":"Verbeek","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clon.2026.104171_bib135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0969-8051(94)90059-0","article-title":"Heterogeneity of circulating calcitonin levels: relations with calcitonin biosynthesis in medullary thyroid carcinomas","volume":"21","author":"Guliana","year":"1994","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.clon.2026.104171_bib136","doi-asserted-by":"crossref","unstructured":"Unal MC, Bayraktar AC, Uslu T, Yener S. Multiple immunoassay interference in a patient with falsely elevated c alcitonin. Arch Endocrinol Metab.68. https:\/\/doi.org\/10.20945\/2359-4292-2023-0074.","DOI":"10.20945\/2359-4292-2023-0074"},{"key":"10.1016\/j.clon.2026.104171_bib137","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.747704","article-title":"Serum calcitonin-negative medullary thyroid carcinoma: A case series of 19 patients in a single center","volume":"12","author":"Kim","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.clon.2026.104171_bib138","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.clon.2026.104171_bib139","article-title":"Management of medullary thyroid cancer based on variation of carcinoembryonic antigen and calcitonin","volume":"15","author":"Wang","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clon.2026.104171_bib140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/cen.15287","article-title":"Combining procalcitonin and calcitonin for the diagnosis of medullary thyroid cancer: a two-step approach","volume":"103","author":"Clausi","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.clon.2026.104171_bib141","doi-asserted-by":"crossref","unstructured":"Rosario PW, Mour\u00e3o GF. Diagnostic utility of procalcitonin for sporadic medullary thyroid carcinoma in patients with nodular disease and mild or moderate hypercalcitoninemia. Horm Metab Res.54:220-223. https:\/\/doi.org\/10.1055\/a-1773-1127.","DOI":"10.1055\/a-1773-1127"},{"key":"10.1016\/j.clon.2026.104171_bib142","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/ERC-17-0389","article-title":"Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients","volume":"25","author":"Romeo","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clon.2026.104171_bib143","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejca.2018.08.013","article-title":"Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer","volume":"103","author":"Allin","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2026.104171_bib144","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13143443","article-title":"Translational utility of liquid biopsies in thyroid cancer management","volume":"13","author":"Wijewardene","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clon.2026.104171_bib145","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154941","article-title":"Circulating tumor DNA: current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clon.2026.104171_bib146","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1210\/jc.2017-01039","article-title":"Prognostic significance of circulating RET M918T mutated tumor DNA in patients with advanced medullary thyroid carcinoma","volume":"102","author":"Cote","year":"2017","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655526001421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:24:37Z","timestamp":1781825077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655526001421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":146,"alternative-id":["S0936655526001421"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2026.104171","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Medullary Thyroid Carcinoma: Integrating World Health Organization Grading and Molecular Targets for Precision Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2026.104171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Royal College of Radiologists. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104171"}}